Carl Hansen, AbCellera CEO
February 14, 2022 07:06 AM EST
FDA+
Coronavirus

As Omi­cron rages, FDA clears Eli Lil­ly/Ab­Celler­a's new an­ti­body days af­ter $720M sup­ply deal

Amber Tong

The FDA has au­tho­rized a new Covid-19 an­ti­body from Eli Lil­ly and Ab­Cellera, adding a much-need­ed weapon to the ar­se­nal fight­ing against Omi­cron.

Just days …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times